NVO News

Latest breaking news and updates for NVO stock.

Track all markets on TradingView

Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025

Bagsværd, Denmark, 20 August 2025 – Novo Nordisk today announced new data showing the cardiovascular protective benefits of Wegovy® and Ozempic® will be presented at the European Society of Cardiol...

What is the likely short‑term stock price reaction to the ESC Congress presentation and could it trigger any significant trading volume spikes? Will competitors like Eli Lilly or Pfizer launch counter‑claims or new data that could dilute the market impact of these results? How will the announced cardiovascular data for Wegovy® and Ozempic® affect Novo Nordisk's revenue outlook and earnings guidance?
Clinical trials
about 2 hours ago
Read more globenewswire

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated pe...

How could this insider activity impact short‑term price volatility and liquidity, and should it affect our trading strategy or position sizing? Do the insiders' actions suggest confidence or concern about Novo Nordisk's near‑term outlook, and how might that influence market sentiment? What were the size, direction (buy or sell), and timing of the insider transactions disclosed?
Insider
1 day ago
Read more globenewswire

INVESTOR REMINDER: Berger Montague Notifies Novo Nordisk A/S (NYSE: NVO) Investors of a Class Action Lawsuit and Deadline

PHILADELPHIA, Aug. 18, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pha...

When is the deadline for the lawsuit response and what are the possible outcomes that could influence the company's long‑term valuation? What is the potential financial exposure from the lawsuit and how might it impact upcoming earnings forecasts? How will the class action lawsuit affect Novo Nordisk's short‑term stock price and volatility?
Lawsuits
2 days ago
Read more prnewswire

Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not wit...

What is the expected timeline for sales ramp‑up and profitability from the MASH market segment? Will the company launch new marketing campaigns or physician education programs to drive uptake for the MASH indication? How might this approval influence Novo Nordisk's pipeline priorities and R&D spending allocation?
Regulatory
5 days ago
Read more prnewswire

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a sup...

Are there any anticipated partnerships or collaborations to support MASH market penetration that could affect Novo's strategic outlook? How might this news impact short‑term trading volume and volatility of NVO stock? What regulatory or safety considerations remain for Wegovy in the MASH indication?
Approval
5 days ago
Read more globenewswire